Europe

Brexit and the Falsified Medicines Directive

In order to help patients avoid being exposed to falsified medicines, the European Commission developed a series of measures to support patients in identifying licenced suppliers of pharmaceutical medicines, and suppliers to identify whether an end-user pack of medicines was genuine. The measures outlined in the Falsified Medicines Directive (2011/62/EU) have been applied across the European Union (EU), with […]

ETP in Europe: the case of UK, Estonia, Denmark, and Sweden

A report has just been published with cross-country comparison of implementations of electronic transmission of prescriptions: “European e-Prescriptions: Benefits and Success Factors”, by Ulrike Deetjen.

The report describes the economic, health, and societal benefits of e-prescriptions, within different policy structures. Based on previous evidence and expert interviews for case studies of Estonia, the United Kingdom, Denmark, and Sweden, it derives […]

July 14th, 2016|Policy|0 Comments|

The EU Personalised Medicine Observatory (2011-2014?)

Part of the EuroBioForum, the Observatory gives insight into the ‘key players’ in Personalised Medicine in Europe, with an online database publicly available of initiatives per country and/or topic.

http://www.eurobioforum.eu/2028/observatory/

 

NB:

EuroBioForum is funded by the European Commission (DG Research & Innovation), 7th Framework Programme. 
Grant Agreement Number: HEALTH-F4-2010-261453
Duration: 1 January 2011 – 31 December 2014

Implementing transparency at the European Medicines Agency

Sergio Bonini, M.D., Hans-Georg Eichler, M.D., Noël Wathion, Pharm., and Guido Rasi, M.D., explain EMA’s policy and practice  about transparency and sharing of data from clinical trials. In:

Transparency and the European Medicines Agency — Sharing of Clinical Trial Data

N Engl J Med 2014; 371:2452-2455December 25, 2014

http://www.nejm.org/doi/full/10.1056/NEJMp1409464?rss=searchAndBrowse

January 8th, 2015|Regulation, Research|0 Comments|

On value base pricing and uncertainty of cost-effectiveness

A new study by colleagues at LSE, Alessandra Ferrario and Panos Kanavos:

Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden, Social Science & Medicine, Volume 124, January 2015, Pages 39-47,

Available at: http://www.sciencedirect.com/science/article/pii/S0277953614007266

A combination of high prices of new patented medicines, […]

November 24th, 2014|Regulation, Value|0 Comments|

Drug pricing in Europe (In French, from Le Monde)

This article from Le Monde explains how medicines are priced in Europe.
Comment est fixé le prix d’un médicament
http://www.lemonde.fr/economie/article/2014/09/30/comment-est-fixe-le-prix-d-un-medicament_4497112_3234.html

Especially of relevance the part about really innovative medicines: “pour les produits les plus innovants – une dizaine par an  –, autorisés au niveau européen et qui obtiennent une note élevée de la part de la Commission de la transparence, le prix […]

October 1st, 2014|Value|0 Comments|

On medicines supply – Drug shortages in European countries

A new paper on the problem of drug shortages and the sustainability of the medicine market:

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?

by Kim Pauwels, Isabelle Huys, Minne Casteels and Steven Simoens
BMC Health Services Research, 2014, 14 :438

http://www.biomedcentral.com/1472-6963/14/438
Abstract

Background
Drug shortages are a global problem. While extensively studied in the United States, numbers about drug […]

October 1st, 2014|Regulation, Value|0 Comments|

News: Interpol raid on illegal medical drugs trade [in French]

From Le Monde:

Raid historique d’Interpol contre les pharmacies en ligne

http://www.lemonde.fr/economie/article/2014/05/22/offensive-d-interpol-contre-les-pharmacies-illegales_4423474_3234.html

‘D’après un rapport de la Commission européenne paru en 2012, les médicaments contrefaits sont ainsi les premiers produits saisis aux frontières de l’Union européenne via le trafic postal.
… Dans le monde, 6 % à 15 % du marché mondial de médicaments relève de la contrefaçon, selon l’Organisation mondiale […]

Europe Innovative Medicines Initiative (IMI)

The Innovative Medicines Initiative (IMI) is Europe’s largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. The legislation establishing IMI 2 was approved by the EU Member States on 6 May 2014. IMI 2 will be launched later in 2014 and will run […]

May 9th, 2014|Research|0 Comments|